Press Releases
▪ Avicanna´s Majority Owned Colombian Subsidiary Attains 2021 THC Production Quota and Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Chile – March 29,2021
▪ Avicanna to Participate in Benzinga Biotech Small Cap Conference and the Virtual Life Sciences Investor Forum both taking place on Thursday March 25th – March 25, 2021
▪ Avicanna Enters Multi-level Strategic Partnership with Al Harrington’s, Harrington Wellness Inc., to Commercialize re+PLAY™ Branded Products in Canada and the United States – February 9, 2021
▪ Avicanna Launches RHO Phyto™ Topical Gels in Canada and Initiates Clinical Studies – January 28, 2021
▪ Avicanna Initiates Pre-Clinical and Behavioural Studies on its RHO Phyto™ Formulary with University of Guelph and Provides Research and Management Team Updates – January 21, 2021
▪ Avicanna Advances Pharmaceutical Epilepsy Program with Collaboration with The University Health Network and GMP Manufacturing Of Its First Pharmaceutical Preparation – January 6, 2021
▪ Avicanna Announces Exercise And Closing Of Over-Allotment Option – December 31, 2020
▪ Avicanna To Expand Access To Its Advanced And Evidence-based Rho Phyto Medical Products Through Provincial Retailers Across Canada – December 23, 2020
▪ Avicanna Expands Distribution Network In South America Through Commercial Partnerships In Ecuador And Commercial Export Of Feminized Seeds To Uruguay – December 17, 2020
▪ Avicanna Launches Medical Cannabis Program With Its Rho Phyto™ Formulary Nationwide In Colombia – December 10, 2020
▪ Avicanna Announces Closing of Public Offering of Units – December 8, 2020
▪ Avicanna Announces Overnight Marketed Public Offering of Units – November 12, 2020
▪ Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update – November 12, 2020
▪ Avicanna Enters Agreement to Develop and License Cannabinoid Tablet Formulations for US Distributor Partner – September 29, 2020
▪ Avicanna’s Subsidiary Obtains GPP Certification and Authorization By INVIMA For The Compounding and Sale Of Pharmaceutical Cannabinoid Products With Medical Prescriptions In Colombia – September 14, 2020
▪ Avicanna Advances its Supply Chain Business with Commercial Exports of CBG And CBD into the United States and Germany as well as Industrial Scale THC Quota Granted by the Colombian Authorities – August 24, 2020
▪ Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million – August 18, 2020
▪ Avicanna’s RHO Phyto™ Medical Product Line is Now Available Nation-Wide in Canada Through Medical Cannabis by Shoppers Inc. – August 12, 2020
▪ Avicanna and Red White & Bloom enter Exclusive Partnership for the Distribution and Commercialization of Pura H&W Hemp-Derived CBD-Based Topical Products in the United States – August 11, 2020
▪ Avicanna announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph – July 24, 2020
▪ Avicanna Announces Participation in a Medical Cannabis Real-World Evidence (MC-RWE) Clinical Study Led by the University Health Network in Partnership with Medical Cannabis by Shoppers™ Inc. using its Rho Phyto™ Advanced Medical Cannabis Formulary of Products – July 15, 2020
▪ Avicanna Announces Co-development of a Cannabinoid-based Formulation for Treatment of COVID-19 related Lung Inflammation with Support from the Mitacs Accelerate Program – June 23, 2020
▪ Avicanna to Host Virtual Symposium Titled “Medical Cannabis 2.0” on July 21st, 2020 in Partnership with Medical Cannabis By Shoppers™ in Anticipation of the Launch of its Rho Phyto™ Product Line – June 22, 2020
▪ Avicanna Completes First Ever Export of Feminized Hemp Seeds For Cultivation Use to the United States and Closes the Initial Sale – June 18, 2020
▪ Avicanna Successfully Registers the First Group of its Pura Earth™ CBD-Based Derma-Cosmetic Product Line in the European Union in Preparation for its Commercialization – June 9, 2020
▪ Avicanna Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with World-Class Canadian Manufacturer MediPharm Labs – May 14, 2020
▪ Avicanna Receives Government Support and Approval for First Ever Export of Hemp Seeds From Colombia – May 7, 2020
▪ Avicanna Closes Non-Brokered Private Placement with Group of Strategic Investors and Announces Warrant Re-Pricing – April 21, 2020
▪ Avicanna to Supply Australian Market with Cannabis-Based Medicinal Products Through Distribution Agreement with Cannvalate – February 24, 2020
▪ Avicanna Ranks Highest Amongst Global Cannabis Companies in the SAM Corporate Sustainability Assessment (CSA) – February 6, 2020
▪ Avicanna Closes First Tranche of Private Placement – January 26, 2020
▪ Avicanna Announces Appointment of Benjamin Leavenworth as Independent Director – January 21, 2020
▪ Avicanna Announces the Successful Completion of its Clinical Study Evaluating the Effect of an Emollient Cream Containing 0.5% Cannabidiol on Skin Hydrationr – January 13, 2020
▪ Avicanna Announces Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc., to Distribute Avicanna’s Advanced and Evidence-based Medical Cannabis and Derma-Cosmetic Products Across Canada – January 10, 2020
▪ Avicanna Enters Into USD$5 Million Revolving Credit Facility – December 27, 2019
▪ Avicanna Receives DTC Eligibility for Common Shares on OTCQX – December 5, 2019
▪ Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group – December 3, 2019
▪ Avicanna’s Rho Phyto Branded Products to be Available in California – December 1, 2019
